TD Cowen Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140

Benzinga Newsdesk www.benzinga.com Neutral 49.1%

Neg 0% Neu 49.1% Pos 0%

TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and lowers the price target from $145 to $140.